A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

Phase 2 Not yet recruiting 36 enrolled Hebei Medical University Fourth Hospital

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT or RECIST1.1 assessment to change the following chemoradiotherapy regiment for locally advanced unresectable ESCC.

Timeline

Start: 2025-08-10
Primary completion: 2025-08-10
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adebrelimab	Monoclonal antibody	1200 mg	Intravenous
Subject	Carboplatin	Small molecule	2 unknown	Intravenous
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Subject	Nab-paclitaxel	Small molecule	60 mg/m2	Intravenous
Subject	Nab-paclitaxel	Small molecule	180 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	50 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	135 mg/m2	Intravenous
Subject	fluorouracil	Small molecule	750 mg/m2	Intravenous
Subject	fluorouracil	Small molecule	1000 mg/m2	Intravenous

A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

Summary

Timeline

Drugs

Indications